- Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update
- Revance to Present Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Injection Technique at the 2021 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting
- Revance to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
- Revance to Participate in the Stifel 2021 Virtual Healthcare Conference
- Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update
- Revance to Release Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
Revance Therapeutics Inc (RVNC:NMQ) closed at 15.36, 24.47% above the 52 week low of 12.34 set on Nov 29, 2021.
12.34Nov 29 202133.83Jul 09 2021
Markit short selling activity
|Market cap||1.10bn USD|
|EPS (TTM)||-4.48 |
Data delayed at least 15 minutes, as of Jan 14 2022 21:00 GMT.